Prognosis and Management of Gleason 3 + 4 = 7 (Grade Group 2) Prostate Cancer

Prognosis

• Gleason 3 + 4 = 7 disease has an excellent long‑term outlook, with 10‑year prostate‑cancer‑specific survival exceeding 92 % in population‑based series. (National Comprehensive Cancer Network) 1

Risk Stratification

• NCCN classifies Gleason 3 + 4 = 7 as intermediate‑risk prostate cancer, which can be subdivided into favorable and unfavorable intermediate‑risk groups based on tumor burden and PSA factors. (NCCN) 1, 2, 3
• Favorable intermediate‑risk is defined when all of the following are present:
• Unfavorable intermediate‑risk is identified by any of the following:

Treatment Recommendations Based on Life Expectancy

Patients with Expected Life Span < 10 years

• Observation or active surveillance is an appropriate initial strategy, because definitive therapy often yields more harm than benefit in the context of competing health risks. (American Family Physician; NCCN) 4, 3

Patients with Expected Life Span ≥ 10 years – Favorable Intermediate‑Risk

• Active surveillance is now an acceptable option when patients are fully informed and agree to close monitoring (regular PSA testing and repeat biopsies). (NCCN) 1
• Radical prostatectomy with pelvic lymph‑node dissection is recommended when the estimated risk of nodal involvement is ≥ 2 %. (NCCN) 3
• External‑beam radiation therapy (EBRT) combined with 4–6 months of androgen‑deprivation therapy (ADT) is a guideline‑supported definitive option. (American Family Physician; NCCN) 4, 3
• Brachytherapy alone or in combination with EBRT is also listed as an acceptable definitive modality. (American Family Physician) 4

Patients with Expected Life Span ≥ 10 years – Unfavorable Intermediate‑Risk

• Definitive treatment (radical prostatectomy, EBRT ± ADT, or brachytherapy) is strongly recommended; active surveillance is not appropriate. (NCCN) 1, 2
• The same definitive modalities described for favorable disease are applicable, but observation is excluded. (NCCN) 1, 2

Expected Outcomes After Definitive Therapy

• Following radical prostatectomy in favorable intermediate‑risk patients, the 5‑year biochemical‑recurrence‑free survival rate is approximately 88 %. (NCCN) 1

Active Surveillance Considerations

• Active surveillance should be limited to favorable intermediate‑risk patients who make an informed decision and accept intensive follow‑up. (NCCN) 1
• It is not recommended for patients with unfavorable intermediate‑risk disease. (NCCN) 3

Prostate Cancer Management Based on Gleason Score

Clinical Significance and Prognostic Impact

• A high Gleason score (8-10) indicates aggressive prostate cancer with significantly worse prognosis, requiring definitive treatment with radical prostatectomy or radiation therapy plus 2-3 years of androgen deprivation therapy in patients with life expectancy ≥5 years 5, 6, 7
• The distinction between Gleason 3+4=7 and 4+3=7 is critical, as the predominant pattern 4 in 4+3=7 confers significantly worse prognosis 7
• With each increase in Gleason score, tumor aggressiveness increases proportionally 8, 6

Risk Stratification and Treatment Recommendations

• The American Urological Association recommends risk categories that integrate Gleason score with PSA and clinical stage to guide treatment, including Low Risk, Intermediate Risk, and High Risk 5, 8
• For Low Risk patients (Gleason ≤6, PSA <10 ng/mL, clinical stage T1-T2a), active surveillance is appropriate for life expectancy <10 years, and observation or definitive treatment for ≥10 years 6
• For Intermediate Risk patients (Gleason 3+4=7 or 4+3=7), observation is acceptable only if life expectancy <10 years, and definitive treatment is recommended for ≥10 years 6
• For High Risk patients (Gleason 8-10, OR PSA >20 ng/mL, OR clinical stage T3-T4), aggressive definitive treatment is mandatory, including radical prostatectomy with pelvic lymph node dissection, or external beam radiation therapy plus 2-3 years of androgen deprivation therapy 6, 7, 8

Post-Surgical Management and Pathology Reporting

• After radical prostatectomy, consider adjuvant therapy if adverse pathological features are identified, and PSA should fall below detection level within 2 months post-prostatectomy 7
• The pathology report must specify biopsy core length, tumor involvement length or percentage, Gleason score with proportion of grades 4 and 5, and presence of extraprostatic extension 9, 10, 11, 5